Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447559 · ClinicalTrials.gov registry record · Phase 4
Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study
A Phase 4 study, sponsored by Monash University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 9,180
- Enrollment target
NCT05447559 is a Phase 4 study that is actively recruiting participants, run by Monash University. The registered enrollment target is 9,180 participants.
The verdict
NCT05447559, a Phase 4 study, is actively recruiting participants, sponsored by Monash University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 9,180 participants
- Enrollment target
Study Summary
This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A), to 24 hours (Arm B) and, to 48 hours (Arm C) of IV cefazolin and placebo postoperative surgical antimicrobial prophylaxis in patients undergoing cardiac surgery
Interventions
- DRUG Cefazolin
- DRUG Water for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,180 participants |
| Start Date | 2023-02-07 |
| Est. Completion | 2028-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05447559
The ClinicalTrials.gov registry entry for NCT05447559 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 9,180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Monash University, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cefazolin is the first listed.
NCT05447559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05447559 about?
NCT05447559 is a clinical study titled "Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study". This multicentre, adaptive, pragmatic, double-blind, three-arm, placebo-controlled, randomised, non-inferiority clinical trial will compare the incidence of surgical site infection and other healthcare associated infections, health economic and microbiological impact after intraoperative only (Arm A...
What is the current status of trial NCT05447559?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 9,180 participants. The study started on 2023-02-07. Estimated completion is 2028-06.
What interventions are being tested in trial NCT05447559?
The interventions under investigation include: Cefazolin (DRUG), Water for injection (DRUG).
Who is sponsoring clinical trial NCT05447559?
This trial is sponsored by Monash University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.